Navigation Links
InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
Date:1/4/2012

BRISBANE, Calif., Jan. 4, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it will report unaudited fourth quarter 2011 revenue related to sales of Esbriet® (pirfenidone) in Germany, as well as other metrics related to the Esbriet launch, prior to the open of the U.S. markets on Thursday, January 5, 2012.  A live conference call and webcast will be hosted by InterMune at 8:30 a.m. Eastern time that same day.  InterMune also plans to report additional efficacy and survival data from the ongoing RECAP extension study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF).  The company will review its plans to gain reimbursement for Esbriet across Europe and an expert in German drug reimbursement law will answer questions on the call.  Additionally, the company will update its expense guidance for 2011 and will provide forward-looking expense guidance for the full year 2012.  

Interested investors and others may participate in the conference call by dialing 888-567-5125 (U.S.) or 706-643-9223 (international), conference ID# 40200495.  To access the live webcast of the call, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A replay of the webcast and teleconference will be available on the company's website approximately three hours after the call and will remain available until the company's next earnings call.

A telephonic replay will be available for 10 business days following the call and can be accessed by dialing 855-859-2056 (U.S.) or 404-537-3406 (international), and entering the conference ID# 40200495. 

About InterMune
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases.  In pulmonology, InterMune is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved worldwide for IPF, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial in the United States.  Pirfenidone is also approved for the treatment of IPF in Japan, where it is marketed by Shionogi & Co. Ltd. under the trade name Pirespa®.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. InterMune to Present at Canaccord Adams Conference
2. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
3. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
4. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
5. InterMune to Release Third Quarter 2008 Financial Results on November 6
6. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
7. InterMune to Present at Deutsche Bank Biotech Boston Confab
8. InterMune to Present at J.P. Morgan Healthcare Conference
9. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
10. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
11. InterMune Announces Issuance of U.S. Patent for ITMN-191
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... A best-selling author and an ... “Grit” author Angela Duckworth and her team at Character Lab have joined Philadelphia’s ... international law firm with decades of experience supporting high-growth companies in the technology ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... outbreak is about to be eliminated, said Lyle Probst, President, CEO and Founder ... technologies different than other pathogen detection solutions, Probst said, “Sample preparation takes ...
(Date:9/19/2017)... ... September 19, 2017 , ... Molecular Devices, ... with Cytena GmbH to launch the CloneSelect™ Single-Cell Printer™ in North America. ... single cells and provide visual documentation of monoclonality for use in cell line ...
(Date:9/18/2017)... , ... September 18, 2017 , ... ... residues to produce biochar, briquettes, and torrefied wood is the topic of a ... , To characterize the potential economic viability of transportable biomass conversion facilities for ...
Breaking Biology Technology:
(Date:7/20/2017)... Delta (NYSE: DAL ) customers now can use fingerprints instead ... National Airport (DCA). ... Delta launches biometrics to board aircraft at Reagan Washington National Airport ... Delta,s biometric boarding pass experience that launched in ... the boarding process to allow eligible Delta SkyMiles Members who are enrolled ...
(Date:5/23/2017)... , May 23, 2017  Hunova, the first robotic gym for the ... been officially launched in Genoa, Italy . The first ... and the USA . The technology was developed ... market by the IIT spin-off Movendo Technology thanks to a 10 million ... News Release, please click: ...
(Date:4/24/2017)... -- Janice Kephart , former 9/11 Commission ... LLP (IdSP) , today issues the following statement: ... 6, 2017 Executive Order: Protecting the Nation ... instilled with greater confidence, enabling the reactivation of ... are suspended by until at least July 2017). ...
Breaking Biology News(10 mins):